학술논문
Medication use during pregnancy and the risk of gastroschisis: a systematic review and meta-analysis of observational studies
Document Type
Report
Source
Orphanet Journal of Rare Diseases. January 30, 2024, Vol. 19 Issue 1
Subject
Language
English
ISSN
1750-1172
Abstract
Author(s): Silvia Baldacci[sup.1] , Michele Santoro[sup.1] , Lorena Mezzasalma[sup.1] , Anna Pierini[sup.1,2] and Alessio Coi[sup.1] Introduction Gastroschisis is a rare congenital anomaly of the abdominal wall where part of the [...]
Objectives The aetiology of gastroschisis is considered multifactorial. We conducted a systematic review and meta-analysis to assess whether the use of medications during pregnancy, is associated with the risk of gastroschisis in offspring. Methods PubMed, EMBASE, and Scopus were searched from 1st January 1990 to 31st December 2020 to identify observational studies examining the association between medication use during pregnancy and the risk of gastroschisis. The Newcastle-Ottawa Scale was used for the quality assessment of the individual studies. We pooled adjusted measures using a random-effect model to estimate relative risk [RR] and the 95% confidence interval [CI]. I.sup.2 statistic for heterogeneity and publication bias was calculated. Results Eighteen studies providing data on 751,954 pregnancies were included in the meta-analysis. Pooled RRs showed significant associations between aspirin (RR 1.66, 95% CI 1.16-2.38; I.sup.2 = 58.3%), oral contraceptives (RR 1.52, 95% CI 1.21-1.92; I.sup.2 = 22.0%), pseudoephedrine and phenylpropanolamine (RR 1.51, 95% CI 1.16-1.97; I.sup.2 = 33.2%), ibuprofen (RR 1.42, 95% CI 1.26-1.60; I.sup.2 = 0.0%), and gastroschisis. No association was observed between paracetamol and gastroschisis (RR 1.16, 95% CI 0.96-1.41; I.sup.2 = 39.4%). Conclusions These results suggest that the exposure in the first trimester of pregnancy to over the counter medications (OTC) such as aspirin, ibuprofen, pseudoephedrine and phenylpropanolamine as well as to oral contraceptives, was associated with an increased risk of gastroschisis. However, these associations are significant only in particular subgroups defined by geographic location, adjustment variables and type of control. Therefore, further research is needed to investigate them as potential risk factors for gastroschisis, to assess their safety in pregnancy and to develop treatment strategies to reduce the risk of gastroschisis in offspring. PROSPERO registration number: CRD42021287529. Keywords: Gastroschisis, Medication, Systematic review, Meta-analysis, Risk factors, Observational studies
Objectives The aetiology of gastroschisis is considered multifactorial. We conducted a systematic review and meta-analysis to assess whether the use of medications during pregnancy, is associated with the risk of gastroschisis in offspring. Methods PubMed, EMBASE, and Scopus were searched from 1st January 1990 to 31st December 2020 to identify observational studies examining the association between medication use during pregnancy and the risk of gastroschisis. The Newcastle-Ottawa Scale was used for the quality assessment of the individual studies. We pooled adjusted measures using a random-effect model to estimate relative risk [RR] and the 95% confidence interval [CI]. I.sup.2 statistic for heterogeneity and publication bias was calculated. Results Eighteen studies providing data on 751,954 pregnancies were included in the meta-analysis. Pooled RRs showed significant associations between aspirin (RR 1.66, 95% CI 1.16-2.38; I.sup.2 = 58.3%), oral contraceptives (RR 1.52, 95% CI 1.21-1.92; I.sup.2 = 22.0%), pseudoephedrine and phenylpropanolamine (RR 1.51, 95% CI 1.16-1.97; I.sup.2 = 33.2%), ibuprofen (RR 1.42, 95% CI 1.26-1.60; I.sup.2 = 0.0%), and gastroschisis. No association was observed between paracetamol and gastroschisis (RR 1.16, 95% CI 0.96-1.41; I.sup.2 = 39.4%). Conclusions These results suggest that the exposure in the first trimester of pregnancy to over the counter medications (OTC) such as aspirin, ibuprofen, pseudoephedrine and phenylpropanolamine as well as to oral contraceptives, was associated with an increased risk of gastroschisis. However, these associations are significant only in particular subgroups defined by geographic location, adjustment variables and type of control. Therefore, further research is needed to investigate them as potential risk factors for gastroschisis, to assess their safety in pregnancy and to develop treatment strategies to reduce the risk of gastroschisis in offspring. PROSPERO registration number: CRD42021287529. Keywords: Gastroschisis, Medication, Systematic review, Meta-analysis, Risk factors, Observational studies